Regeneron Pharmaceuticals Stock Probability Of Bankruptcy

REGN Stock  USD 778.50  9.50  1.21%   
Regeneron Pharmaceuticals' chance of distress is below 1% at this time. The company is very unlikely to encounter any financial hardship in the next two years. Odds of distress shows the probability of financial torment over the next two years of operations under current economic and market conditions. All items used in analyzing the odds of distress are taken from the Regeneron balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out Regeneron Pharmaceuticals Piotroski F Score and Regeneron Pharmaceuticals Altman Z Score analysis.
To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.
  
As of the 11th of December 2024, Market Cap is likely to grow to about 40.3 B. Also, Enterprise Value is likely to grow to about 40.3 B

Regeneron Pharmaceuticals Company odds of distress Analysis

Regeneron Pharmaceuticals' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Probability Of Bankruptcy

 = 

Normalized

Z-Score

More About Probability Of Bankruptcy | All Equity Analysis

Current Regeneron Pharmaceuticals Probability Of Bankruptcy

    
  Less than 1%  
Most of Regeneron Pharmaceuticals' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Regeneron Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Regeneron Pharmaceuticals probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Regeneron Pharmaceuticals odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Regeneron Pharmaceuticals financial health.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.298
Earnings Share
40.46
Revenue Per Share
128.691
Quarterly Revenue Growth
0.106
Return On Assets
0.0741
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Regeneron Probability Of Bankruptcy Driver Correlations

Understanding the fundamental principles of building solid financial models for Regeneron Pharmaceuticals is extremely important. It helps to project a fair market value of Regeneron Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Regeneron Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Regeneron Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Regeneron Pharmaceuticals' interrelated accounts and indicators.
1.0-0.060.990.980.970.980.830.980.630.930.870.290.950.761.00.960.990.650.88-0.910.760.610.9-0.67
1.0-0.090.990.960.950.970.850.960.60.940.850.270.940.741.00.940.990.640.87-0.90.770.620.9-0.69
-0.06-0.090.0-0.010.02-0.090.03-0.08-0.080.01-0.26-0.12-0.15-0.26-0.090.160.03-0.26-0.13-0.190.10.16-0.04-0.15
0.990.990.00.960.950.970.870.950.570.950.820.190.90.690.990.960.990.590.86-0.930.780.630.91-0.7
0.980.96-0.010.960.990.990.710.980.710.850.870.320.950.760.970.970.960.660.92-0.950.660.50.91-0.56
0.970.950.020.950.990.970.710.990.740.840.890.340.960.820.960.980.960.690.88-0.940.670.540.87-0.57
0.980.97-0.090.970.990.970.750.980.690.850.890.270.930.790.980.960.960.630.94-0.940.630.460.94-0.53
0.830.850.030.870.710.710.750.720.210.940.540.130.70.440.840.750.870.40.59-0.710.810.690.72-0.79
0.980.96-0.080.950.980.990.980.720.780.840.910.290.960.840.970.960.960.670.9-0.920.660.540.88-0.55
0.630.6-0.080.570.710.740.690.210.780.410.750.240.70.760.610.680.590.530.69-0.660.280.280.55-0.18
0.930.940.010.950.850.840.850.940.840.410.70.180.830.570.940.860.950.520.69-0.790.90.790.79-0.85
0.870.85-0.260.820.870.890.890.540.910.750.70.280.90.920.860.850.820.640.81-0.770.530.470.75-0.41
0.290.27-0.120.190.320.340.270.130.290.240.180.280.420.350.260.230.250.320.25-0.170.250.120.18-0.04
0.950.94-0.150.90.950.960.930.70.960.70.830.90.420.850.940.90.920.810.81-0.830.690.570.78-0.57
0.760.74-0.260.690.760.820.790.440.840.760.570.920.350.850.750.750.710.660.72-0.670.420.370.62-0.29
1.01.0-0.090.990.970.960.980.840.970.610.940.860.260.940.750.950.990.640.87-0.90.770.620.9-0.68
0.960.940.160.960.970.980.960.750.960.680.860.850.230.90.750.950.970.590.86-0.970.70.580.88-0.61
0.990.990.030.990.960.960.960.870.960.590.950.820.250.920.710.990.970.620.84-0.930.780.650.89-0.71
0.650.64-0.260.590.660.690.630.40.670.530.520.640.320.810.660.640.590.620.52-0.50.470.370.46-0.34
0.880.87-0.130.860.920.880.940.590.90.690.690.810.250.810.720.870.860.840.52-0.910.480.210.97-0.26
-0.91-0.9-0.19-0.93-0.95-0.94-0.94-0.71-0.92-0.66-0.79-0.77-0.17-0.83-0.67-0.9-0.97-0.93-0.5-0.91-0.58-0.41-0.930.48
0.760.770.10.780.660.670.630.810.660.280.90.530.250.690.420.770.70.780.470.48-0.580.890.58-0.81
0.610.620.160.630.50.540.460.690.540.280.790.470.120.570.370.620.580.650.370.21-0.410.890.31-0.9
0.90.9-0.040.910.910.870.940.720.880.550.790.750.180.780.620.90.880.890.460.97-0.930.580.31-0.4
-0.67-0.69-0.15-0.7-0.56-0.57-0.53-0.79-0.55-0.18-0.85-0.41-0.04-0.57-0.29-0.68-0.61-0.71-0.34-0.260.48-0.81-0.9-0.4
Click cells to compare fundamentals
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
Competition

Based on the latest financial disclosure, Regeneron Pharmaceuticals has a Probability Of Bankruptcy of 1.0%. This is 97.69% lower than that of the Biotechnology sector and 98.18% lower than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 97.49% higher than that of the company.

Regeneron Probability Of Bankruptcy Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Regeneron Pharmaceuticals' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Regeneron Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Regeneron Pharmaceuticals by comparing valuation metrics of similar companies.
Regeneron Pharmaceuticals is currently under evaluation in probability of bankruptcy category among its peers.

Regeneron Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Regeneron Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Regeneron Pharmaceuticals' managers, analysts, and investors.
Environmental
Governance
Social

Regeneron Fundamentals

About Regeneron Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Regeneron Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regeneron Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regeneron Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Pair Trading with Regeneron Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Regeneron Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Regeneron Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Regeneron Stock

  0.86VALN Valneva SE ADRPairCorr
  0.83ERNA Eterna TherapeuticsPairCorr

Moving against Regeneron Stock

  0.95BMY Bristol Myers SquibbPairCorr
  0.85GILD Gilead SciencesPairCorr
  0.74ESPR Esperion TherapeuticsPairCorr
  0.51DYAI Dyadic InternationalPairCorr
  0.39DNA Ginkgo Bioworks HoldingsPairCorr
The ability to find closely correlated positions to Regeneron Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Regeneron Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Regeneron Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Regeneron Pharmaceuticals to buy it.
The correlation of Regeneron Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Regeneron Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Regeneron Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Regeneron Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:
Check out Regeneron Pharmaceuticals Piotroski F Score and Regeneron Pharmaceuticals Altman Z Score analysis.
To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.298
Earnings Share
40.46
Revenue Per Share
128.691
Quarterly Revenue Growth
0.106
Return On Assets
0.0741
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.